Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG – Get Free Report)’s share price hit a new 52-week low during mid-day trading on Friday. The stock traded as low as $14.11 and last traded at $14.30, with a volume of 5,236 shares. The stock had previously closed at $14.88.
Wall Street Analyst Weigh In
A number of brokerages have weighed in on AAPG. William Blair assumed coverage on shares of Ascentage Pharma Group International in a research report on Friday, October 16th. They issued an “outperform” rating for the company. JPMorgan Chase & Co. reduced their price objective on Ascentage Pharma Group International from $46.00 to $33.00 and set an “overweight” rating for the company in a research note on Thursday, October 8th. Citizens Jmp initiated coverage on Ascentage Pharma Group International in a research note on Tuesday, October 13th. They set a “market outperform” rating and a $35.00 target price for the company. BTIG Research reissued a “buy” rating and issued a $48.00 price objective on shares of Ascentage Pharma Group International in a research note on Friday, August 21st. Finally, Citigroup initiated coverage on shares of Ascentage Pharma Group International in a research report on Wednesday, October 14th. They set a “buy” rating and a $46.00 target price on the stock. Two analysts have rated the stock with a Strong Buy rating and twelve have assigned a Buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $43.90.
View Our Latest Stock Analysis on Ascentage Pharma Group International
Ascentage Pharma Group International Price Performance
The company has a current ratio of 1.22, a quick ratio of 1.18 and a debt-to-equity ratio of 1.09. The firm’s fifty day moving average price is $15.91 and its 200-day moving average price is $20.27.
Ascentage Pharma Group International (NASDAQ:AAPG – Get Free Report) last posted its quarterly earnings results on Wednesday, August 19th. The company reported ($0.65) earnings per share (EPS) for the quarter. The business had revenue of $22.24 million during the quarter. On average, analysts anticipate that Ascentage Pharma Group International – Unsponsored ADR will post -2.43 earnings per share for the current year.
About Ascentage Pharma Group International
Ascentage Pharma Group International is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for cancer and other serious diseases.
Featured Articles
- Five stocks we like better than Ascentage Pharma Group International
- Breaching the Valuation: The Real Reason Fortinet Dropped
- Microsoft Earnings Expose a Growing Divide in the Magnificent 7 AI Trade
- Silicon Shock: Intel’s 25% Valuation Reset
- Advanced Micro Devices’ Meta Platforms Partnership Goes Beyond a $1 Billion Investment
Receive News & Ratings for Ascentage Pharma Group International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascentage Pharma Group International and related companies with MarketBeat.com's FREE daily email newsletter.
